Physician profile
Daniel Lee Murphy
NPI 1619632676
$1,863.71
in general payments reported to CMS, 2019-2025
20 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $87.07 · 2022: $414 · 2023: $650 · 2024: $273 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $608.21 | 2022-2025 | Lifevest |
| Pfizer INC. | $200.56 | 2023-2024 | |
| Boston Scientific Corporation | $184.70 | 2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $170.95 | 2022-2025 | Camzyos |
| Actelion Pharmaceuticals US, INC. | $157.33 | 2023 | Opsumit, Uptravi |
| Kedrion Biopharma, INC. | $110.26 | 2022 | |
| Merck Sharp & Dohme LLC | $78.32 | 2022-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $77.91 | 2021-2023 | Xarelto |
| Abbott Laboratories | $45.51 | 2023-2024 | Diamondback Coronary, Gallant |
| Kiniksa Pharmaceuticals International, Plc | $30.26 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $28.61 | 2021-2024 | Farxiga |
| Abiomed | $25.94 | 2023 | Impella |
| Amarin Pharma, INC. | $23.20 | 2021 | |
| Cardiovascular Systems INC. | $19.82 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.93 | 2023 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $18.92 | 2021 | |
| Amgen INC. | $16.96 | 2024 | Repatha |
| Scpharmaceuticals INC. | $16.95 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $16.00 | 2023 | Inpefa |
| Terumo Medical Corporation | $14.37 | 2025 | Tr Band, Navicross, Glidesheath Slender |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.